| Mechanisms of immune evasion in acute lymphoblastic leukemia A Pastorczak, K Domka, K Fidyt, M Poprzeczko, M Firczuk Cancers 13 (07), 1536, 2021 | 50 | 2021 |
| Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax K Fidyt, A Pastorczak, J Cyran, NT Crump, A Goral, J Madzio, ... Oncogene 41 (11), 1600-1609, 2022 | 16 | 2022 |
| cROSsing the line: Between beneficial and harmful effects of reactive oxygen species in B-cell malignancies K Domka, A Goral, M Firczuk Frontiers in immunology 11, 1538, 2020 | 16 | 2020 |
| Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells A Dabkowska, K Domka, M Firczuk Frontiers in Immunology 15, 1363102, 2024 | 5 | 2024 |
| Optimizing the therapeutic potential of tyrosine kinase inhibitors in chemo-immunotherapy of B-cell acute lymphoblastic leukemia involving rituximab K Domka, M Poprzeczko, Z Urbanska, L Komorowski, A Pastorczak, ... Cancer Research 82 (12_Supplement), 3324-3324, 2022 | 1 | 2022 |
| P339: BOOSTING THE EFFICACY OF CD20-TARGETING IMMUNOTHERAPY IN B CELL ACUTE LYMPHOBLASTIC LEUKEMIA M Poprzeczko, K Domka, A Pastorczak, K Fidyt, L Komorowski, ... HemaSphere 6, 239-240, 2022 | | 2022 |
| Pharmacological Induction of NOXA Sensitizes High-Risk B Cell Acute Lymphoblastic Leukemia Cells to Venetoclax K Fidyt, J Cyran, A Pastorczak, NT Crump, A Muchowicz, A Goral, ... Blood 136, 17-18, 2020 | | 2020 |
| Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor … K Domka, A Dąbkowska, M Janowska, Z Urbańska, A Pastorczak, ... Haematologica, 2020 | | 2020 |
